NSC 23766

For research use only.

Catalog No.S8031

38 publications

NSC 23766 Chemical Structure

Molecular Weight(MW): 530.96

NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by guanine nucleotide exchange factors (GEFs) with IC50 of ~50 μM in a cell-free assay; does not inhibit the closely related targets, Cdc42 or RhoA.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 140 In stock
USD 87 In stock
USD 110 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's NSC 23766 has been cited by 38 publications

Purity & Quality Control

Choose Selective Rho Inhibitors

Biological Activity

Description NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by guanine nucleotide exchange factors (GEFs) with IC50 of ~50 μM in a cell-free assay; does not inhibit the closely related targets, Cdc42 or RhoA.
Targets
Rac GTPase [1]
(Cell-free assay)
50 μM
In vitro

NSC23766 is identified to fit into a surface groove of Rac1 known to be critical for GEF specification. NSC23766 effectively inhibits Rac1 binding and activation by the Rac-specific GEF Trio or Tiam1 in a dose-dependent manner without interfering with the closely related Cdc42 or RhoA binding or activation by their respective GEFs or with Rac1 interaction with BcrGAP or effector PAK1. [1] NSC 23766 is active in regulating Rac GTPase functions on cytoskeleton and many cell functions including cell cycle, cell growth, adhesion, migration and gene transcription. NSC 23766 (50 μM) potently blocks serum or platelet-derived growth factor-induced Rac1 activation and lamellipodia formation without affecting the activity of endogenous Cdc42 or RhoA in NIH 3T3 cells. NSC 23766 reduces Trio or Tiam1 but not Vav, Lbc, Intersectin, or a constitutively active Rac1 mutant-stimulated NIH 3T3 cells growth and suppresses Trio, Tiam1, or Ras-induced cell transformation. NSC23766 dose-dependently inhibits PC-3 cells proliferation and anchorage-independent growth. 25 μM NSC23766 inhibits the PC-3 cell invasion through Matrigel by 85%. [1] 50 μM NSC 23766 inhibits thrombin-induced activation of Rac1 an d Rac2 in human platelets, as well as platelet aggregation. [2] NSC23766 prevents Aβ40 and Aβ42 production in swAPP-HEK293cells without affecting Notch and sAPPα. NSC23766 prevents γ-secretase activity in cell, but not act as a direct γ-secretase inhibitor. NSC23766 dose-dependently reduces levels of secreted and intracellular Aβ40 with IC50 of 48.94 μM. 50 μM NSC 23766 inhibits release of Aβ42 by 57.97%. [3] NSC23766 regulates endothelial nitric oxide synthase expression and endothelial function. 100 μM NSC23766 represses the eNOS promoter activity by 60% in bovine aortic ECs and by 30% to 35% in bEND.3 cells. Inhibition of Rac1 with NSC23766 destabilizes eNOS mRNA and shortens its half-life to 17 hours. NSC23766 dose-dependently attenuates ACh-induced relaxation of wild-type mice aortic rings. [4] NSC23766 inhibits cell growth and induces apoptosis. NSC23766 decreases MDA-MB-468 and MDA-MB-231 cells viability in a dose-dependent manner with IC50 of ~10 μM, which is not correlated with the status of estrogen receptor (ER), progesterone receptor (PR), Her2, and p53 mutation. NSC23766 has little effect on the survival of the MCF12A normal mammary epithelial cells. After 24 hours expose to NSC 23766, MDA-MB-231 cells showes an increase from 41% to 65% in G1 phase and a concomitant decrease in S and G2-M phases. 100 μM NSC23766 induces a six-fold increase of apoptotic MDA-MB-468. The inhibition of NSC23766 on cell cycle arrest or apoptosis in breast cancer cells is mediated by downregulation of cyclin D1, survivin, and X-linked inhibitor of protein apoptosis. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
RBMECs MknJSpVv[3Srb36gRZN{[Xl? NFjzWGMyODEEoN88UeKh MWOzNOKhdWmw M{Pm[YJtd2OtZYOgOmJvgi2lQV3QMY1m\GmjdHXkJIFkfGm4YYTpc44hd2ZiUnHjNUBqdiCHTVHQMWlKNXS{ZXH0[YQhWkKPRVPz NGW1NZAzPjN3OECzPS=>
A431 NH7oZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:xcW14OTByIN88US=> MmPhNlQwPDhxN{KgbC=> M1jweYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz MWSyOVExQTN{Nx?=
SW480  NX7LS3hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{S4PFExOCEQvF2= NHP4fHUzPC92OD:3NkBp NVfYT5ZMcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? MVGyOVExQTN{Nx?=
U2-OS M3ixbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSxNFAh|ryP M4n1U|I1NzR6L{eyJIg> M4fSe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz M3;XXFI2OTB7M{K3
A431 M4nTd2Z2dmO2aX;uJGF{e2G7 NEnIbGEyODBizszN MXiyOEBp NELkdmxFVVOR MlPubY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckB1cGViR{GgdIhie2YEoB?= NHrWc|UzPTFyOUOyOy=>
SW480  NEKxR|ZHfW6ldHnvckBCe3OjeR?= MlLRNVAxKM7:TR?= NYXFZW1NOjRiaB?= M{XoZmROW09? NXTYenpVcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiC2aHWgS|EheGijc3ZCpC=> NEDmNGszPTFyOUOyOy=>
U2-OS MnyzSpVv[3Srb36gRZN{[Xl? NVXRbGRsOTByIN88US=> MYiyOEBp NVzMWIlCTE2VTx?= NUPEeIhrcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiC2aHWgS|EheGijc3ZCpC=> NYLnTlZnOjVzMEmzNlc>
NIH3T3  NI\1O2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K1VVExOCEQvF2= MXKyOOKhcA>? MXToZZMhdm9ic3nncolncWOjboSgbY1x[WO2IH;uJINmdGxidnnhZoltcXS7 NITTTHIzPTB|N{C2NC=>
Ki-67+ CLL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\iOVAhyrWP MnfiOUBl M13wVoRm[3KnYYPld{B1cGViboXtZoVzKG:oIFvpMVY4M8LiQ1zMJINmdGy| M1nTVlI1PTBzMkG3
U87MG M{jjd2NmdGxiVnnhZoltcXS7IFHzd4F6 NYDJOHdrPTBibV2= MVSxOFQhcA>? NFOwWY1FVVOR NGW4e4RmgGirYnn0d{B{gW6ncnfpd5Rq[yCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5R{KGOxbXLpcoVlKHS{ZXH0cYVvfCC5aYToJIVzdG:2aX7pZuKh MYWyN|g{OjF{MB?=
A172MG M4TGTWNmdGxiVnnhZoltcXS7IFHzd4F6 NEDxS5M2OCCvTR?= NXXwRlJpOTR2IHi= M1XRfGROW09? NX7jXG4{\XiqaXLpeJMhe3mwZYLnbZN1cWNiYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1eyClb33ibY5m\CC2cnXheI1mdnRid3n0bEBmemyxdHnubYLDqA>? NGDs[GkzOzh|MkGyNC=>
T98MG MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2mwelUxKG2P NFPkcnEyPDRiaB?= NE\0OYtFVVOR NYDzS|Jj\XiqaXLpeJMhe3mwZYLnbZN1cWNiYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1eyClb33ibY5m\CC2cnXheI1mdnRid3n0bEBmemyxdHnubYLDqA>? NYH2[op{OjN6M{KxNlA>
PC38 MofPR4VtdCCYaXHibYxqfHliQYPzZZk> M{HMeFUxKG2P NYjTTmp{OTR2IHi= M1TLd2ROW09? NX7WRYxE\XiqaXLpeJMhe3mwZYLnbZN1cWNiYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1eyClb33ibY5m\CC2cnXheI1mdnRid3n0bEBmemyxdHnubYLDqA>? NHW4fW8zOzh|MkGyNC=>
PC40 M4PGemNmdGxiVnnhZoltcXS7IFHzd4F6 NUL3NW1yPTBibV2= M4HrT|E1PCCq NEPzfYpFVVOR M17ycoV5cGmkaYTzJJN6dmW{Z3nzeIlkKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeJMh[2:vYnnu[YQhfHKnYYTt[Y51KHerdHig[ZJtd3SrbnnixsA> NG\Dc5czOzh|MkGyNC=>
U87MG MljGSpVv[3Srb36gRZN{[Xl? NX3zRZdIPTBibV2= MYSyOEBp MV\EUXNQ NFXLdWxmdmijbnPld{B1cGViYX70bY1q\3KjdH;yfUBm\m[nY4Sgc4Yh\XKub4Tpcolj M1O5eFI{QDN{MUKw
A172MG NUj2cWVzTnWwY4Tpc44hSXO|YYm= M17He|UxKG2P M2Ty[FI1KGh? M3;QS2ROW09? M{fJdoVvcGGwY3XzJJRp\SCjboTpcYloemG2b4L5JIVn\mWldDDv[kBmemyxdHnubYI> M1HoTVI{QDN{MUKw
T98MG Mn\VSpVv[3Srb36gRZN{[Xl? NEPlWnc2OCCvTR?= NHXBc5AzPCCq M1T6V2ROW09? Mn7h[Y5p[W6lZYOgeIhmKGGwdHntbYdz[XSxcomg[YZn\WO2IH;mJIVzdG:2aX7pZi=> M2nZTVI{QDN{MUKw
NCI-H1703 NYTjTZlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYX4S|RxOC13MECg{txO NHfOOHAzPCCq M{XMWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MkHmNlI2PDlzNkC=
NCI-H1703 MWPGeY5kfGmxbjDBd5NigQ>? M4P4b|ExOCEQvHevcYw> M3j2WVI1KGh? NFfZPGt{dG:5czDwdo9oemW|c3nvckB1cHKxdXfoJJRp\SCJMdMgdIhie2Vib3[geIhmKGOnbHygZ5lkdGV? NFntR44zOjV2OUG2NC=>
NCI-H1703 Mo\tSpVv[3Srb36gRZN{[Xl? MXewMVUxOCEQvF2= MU[yOEBp M3yyV4RqdWmwaYPo[ZMh[mG|YXygUmYu|rqEIHHjeIl3cXS7IHTvd4Uh\GWyZX7k[Y51dHoEoB?= MYSyNlU1QTF4MB?=
SKBR3 MV3GeY5kfGmxbjDBd5NigQ>? MmXSOVAh|ryP MlLVNlQhcA>? NXW5bmRKcW6qaXLpeJMhWmGlMTDhZ5RqfmG2aX;u MmDqNlE6PDN6MkW=
SKBR3-pMKO.1 MoHrSpVv[3Srb36gRZN{[Xl? MnTtOVAh|ryP NXjlZ|hZOjRiaB?= MUnpcohq[mm2czDSZYMyKGGldHn2ZZRqd25? MWGyNVk1Ozh{NR?=
MCF7 NYDkdXpXS3m2b4TvfIlkcXS7IFHzd4F6 NFntOYExNTFyMDFOwG0> NX\pWnFuPDhiaB?= NX;CRVlL\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NEDtOYEzODVzNUm0NC=>
T47D Ml7mR5l1d3SxeHnjbZR6KEG|c3H5 NFTFV3QxNTFyMDFOwG0> MUm0PEBp MX3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1[1dlIxPTF3OUSw
MDA-MB-468 NGe0RmZEgXSxdH;4bYNqfHliQYPzZZk> MVGwMVExOCEQvF2= M1zjU|Q5KGh? MVLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NYXTcIRYOjB3MUW5OFA>
MDA-MB-231 NFf6SGpEgXSxdH;4bYNqfHliQYPzZZk> NH\WW2YxNTFyMDFOwG0> MX20PEBp NHTTTXRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M4OwZlIxPTF3OUSw
MDA-MB-231 MnzkSpVv[3Srb36gRZN{[Xl? M3;DNlAuOTByIN88US=> NVW1V5FZOjRiaB?= M2i5U5NmdGWldHn2[Yx6KGmwaHnibZR{KFKjY{GgZYN1cX[jdHnvckB4cXSqb4X0JIlvfGW{ZnXybY5oKHerdHigeIhmKGGldHn2bZR6KG:oIITo[UBkdG:|ZXz5JJJmdGG2ZXSgd41idGxiR2TQZZNmKEOmY{Sy MUeyNFUyPTl2MB?=
MDA-MB-231  MV7GeY5kfGmxbjDBd5NigQ>? MnL2NVAxKM7:TR?= M3rS[|Q5KGh? M2L4fYlv[3KnYYPld{B1cGViY3XscEBvfW2kZYKgbY4hTzIEoIDoZZNmKGGwZDDk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IHnuJHMh[W6mIFeyMW0heGijc3XzxsA> M372bVIxPTF3OUSw
MCF7 M2i0VWZ2dmO2aX;uJGF{e2G7 MWexNFAh|ryP NITtc|k1QCCq M4PPSIlv[3KnYYPld{B1cGViY3XscEBvfW2kZYKgbY4hTzIEoIDoZZNmKGGwZDDk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IHnuJHMh[W6mIFeyMW0heGijc3XzxsA> NWfYT4NUOjB3MUW5OFA>
T47D M2e3[WZ2dmO2aX;uJGF{e2G7 NWfjT5h[OTByIN88US=> NXq3fno4PDhiaB?= M1TKeIlv[3KnYYPld{B1cGViY3XscEBvfW2kZYKgbY4hTzIEoIDoZZNmKGGwZDDk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IHnuJHMh[W6mIFeyMW0heGijc3XzxsA> NUXXbGVlOjB3MUW5OFA>
MDA-MB-468 MWnBdI9xfG:|aYOgRZN{[Xl? NYHmPGVwPTBxMUCwJO69VQ>? M1H4TlI1KGh? M33mPYlv\HWlZYOgZZBweHSxc3nz M1X5TVIxPTF3OUSw
MDA-MB-468 NFyzflNHfW6ldHnvckBCe3OjeR?= MV2xNFAh|ryP MnjENlQhcA>? NEm5ToVqdmirYnn0d:Kh[2G|cHHz[U0{KGGldHn2ZZRqd28EoB?= MnTENlA2OTV7NEC=
MDA-MB-468 MUnGeY5kfGmxbjDBd5NigQ>? M{W4OVUxNzFyMDFOwG0> NHrIPFEzPCCq M3nqW4lv[3KnYYPld{BxcG:|cHjvdplt[XSrb36gc4YhUk6NIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NYDwNllqOjB3MUW5OFA>
MDA-MB-231  MlrZSpVv[3Srb36gRZN{[Xl? M2DnN|UxNzFyMDFOwG0> M1ToblI1KGh? NHexPVdqdmO{ZXHz[ZMheGixc4Doc5J6dGG2aX;uJI9nKEqQSzDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MmfXNlA2OTV7NEC=
MDA-MB-468 M1\uemZ2dmO2aX;uJGF{e2G7 M3vnN|UxNzFyMDFOwG0> MnSwOFghcA>? NYrYPYJHcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHnvckBw\iCyNkWgd5VjfW6rdB?= M1zxUlIxPTF3OUSw
MDA-MB-231  Mly5SpVv[3Srb36gRZN{[Xl? MlrqOVAwOTByIN88US=> M33Ub|Q5KGh? MWfpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1cW:wIH;mJJA3PSC|dXL1col1 M2fKTVIxPTF3OUSw
IEC-6  MWjGeY5kfGmxbjDBd5NigQ>? NIe2XWEyOjBiwsXN MlH2OE83NzhiaB?= MXrwdoV3\W62czD0bIUhcW6lcnXhd4VlKGGldHn2ZZRqd25ib3[gSmFMKGG2IE[gZY5lKDhiaB?= M2rMfVIxPDR6NE[x
RA-FLS (RA2)  NWr1[4pJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPhTZA6OjVxNUCg{txO MUixMVkh\A>? MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62IH3hco5meg>? NY\WUJMzOTd4MkKzNFg>
RA1 NWPCUXlCTnWwY4Tpc44hSXO|YYm= M1voWFUxKM7:TR?= MX:yOEBp NVyzb21RcW6qaXLpeJMhVWG2cnnn[YwhcW64YYPpc44> NYOxb2p6OTd4MkKzNFg>
RA2 NELYfHlHfW6ldHnvckBCe3OjeR?= MnewOVAh|ryP MX:yOEBp MV\pcohq[mm2czDNZZRzcWenbDDpcpZie2mxbh?= M2DBbVE4PjJ{M{C4
RA3 Ml3iSpVv[3Srb36gRZN{[Xl? M4rOOVUxKM7:TR?= MWKyOEBp M3zQNYlvcGmkaYTzJG1ifHKrZ3XsJIlvfmG|aX;u M1y1elE4PjJ{M{C4
RA4 M3\N[GZ2dmO2aX;uJGF{e2G7 Mnj3OVAh|ryP NWXkW4lVOjRiaB?= MXvpcohq[mm2czDNZZRzcWenbDDpcpZie2mxbh?= MkLuNVc3OjJ|MEi=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pCREB / CREB; 

PubMed: 25319697     


Rac1 inhibitor NSC23766 decreases CREB phosphorylation at serine 133 (pCREB) in cortical neurons. Left, Temporal profiles of NSC23766 (100 μm) on basal pCREB levels. Right, Dose–response effects of NSC23766 (30 min) application on pCREB. 

OCT4 / SOX2 / Nanog ; 

PubMed: 31338333     


Down-regulation of Rac1-GTP treated with NSC23766 decreased expression of Nanog, Sox2, and Oct4 levels in TUFT1—MDA-MB-231 and TUFT1—HCC1937 cells (n = 3). 

active Rac1 / Rac1 ; 

PubMed: 31338333     


Western blot showed effect of Rac1 inhibitor NSC23766 on Rac1-GTP in MDA-MB-231 cells (n = 3). 

25319697 31338333
Immunofluorescence
IP3K-A / F-actin; 

PubMed: 19890013     


Rac1-specific inhibitor NSC23766 gradually blocked the IP3K-A expression-induced formation of filopodia in HeLa cells. Following transfection of GFP-IP3K-A, HeLa cells were incubated for 24 hrs in medium containing the Rac1 inhibitor. Treatment with 40 µM䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙

BART / Rac1; 

PubMed: 22745590     


S2-013 cells were pretreated with or without the Rac1 inhibitor (NSC23766) and were immunocytochemically stained using anti-BART (green) and anti-Rac1 (red) antibodies. Arrows indicate colocalized BART and Rac1 in lamellipodial-like protrusions; blue, DAP䲧疝Ỵ疞㧀疜膉痘 

19890013 22745590
In vivo NSC23766 induces mobilization of hematopoietic stem cells/progenitors. Intraperitoneal administration of NSC23766 (2.5 mg/kg) into the ‘‘poorly mobilizing ’’ C57Bl/6 mouse strain leads to a two-fold increase in circulating hematopoietic stem cells/progenitors 6 hr after injection. [2] NSC23766 alleviates lipopolysaccharide-induced acute pulmonary injury in mice. Treatment with NSC23766 at 1 or 3mg/kg not only reduces the inflammatory cells infiltration and MPO activities, but also inhibits pro-inflammatory mediators, tumor necrosis factor-α and interleukin-1β, mRNA expression. NSC23766 also reduces Evans Blue and albumin accumulation in LPS-challenged lungs. [6]

Protocol

Kinase Assay:[1]
- Collapse

Rho GTPase activity assay:

Cells are grown in log phase in a 10-cm dish, and are starved in 0.5% serum medium or indicated otherwise for 24 h before lysis in a buffer containing 20 mM Tris HCl (pH 7.6), 100 mM NaCl, 10 mM MgCl2, 1% Nonidet P-40, 10% glycerol, and 1× protease inhibitor mixture. Lysates are clarified, the protein concentrations are normalized, and the GTP-bound Rac1 in the lysates is measured by an effector domain pull-down assay. For the His6-PAK1 PBD pull-down assay, cell lysates are incubated with Ni2+-agarose-immobilized His6-PAK1 PBD domain (∼1 μg each) purified from E. coli for 30 min. The Ni2+-agarose co-precipitates are washed twice in the wash buffer and analyzed by immunoblotting with anti-Rac1 monoclonal antibody.
Cell Research:[5]
- Collapse
  • Cell lines: Human breast cancer cells MDA-MB-468
  • Concentrations: 0-100 μM
  • Incubation Time: 2 days
  • Method: Cells (1.5 × 104/mL) are seeded in each well of 96-well tissue culture plates with 200 μL of medium. After 24 hours of plating, the medium is replaced with 200 μL of fresh medium containing NSC23766 at the indicated concentrations. At the end of the treatment period 20 μL of MTS solution are added to each well and incubated at 37 ℃ for 2 hours. Absorbance at 490 nm is read on a 96-well plate reader.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (188.33 mM)
Water 100 mg/mL warmed (188.33 mM)
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 530.96
Formula

C24H35N7.3HCl

CAS No. 1177865-17-6
Storage powder
in solvent
Synonyms N/A
Smiles Cl.Cl.Cl.CCN(CC)CCCC(C)NC1=NC(=CC(=N1)NC2=CC3=C(N)C=C(C)N=C3C=C2)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Rho Signaling Pathway Map

Tags: buy NSC23766|NSC23766 ic50|NSC23766 price|NSC23766 cost|NSC23766 solubility dmso|NSC23766 purchase|NSC23766 manufacturer|NSC23766 research buy|NSC23766 order|NSC23766 mouse|NSC23766 chemical structure|NSC23766 mw|NSC23766 molecular weight|NSC23766 datasheet|NSC23766 supplier|NSC23766 in vitro|NSC23766 cell line|NSC23766 concentration|NSC23766 nmr|NSC23766 in vivo|NSC23766 clinical trial|NSC23766 inhibitor|NSC23766 Cell Cycle inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID